From Lukas
Hey everyone,
Three developments from the last week that felt worth sharing: a human senolytic trial that moved liver fibrosis, a mitochondrial lipid that steers aging muscle, and a cleaner way to switch on the cell's energy sensor.
Lukas DvorskyFounder of LongevityMate
The Big Signal
A phase-2 senolytic trial moved hard liver histology
What happened
Nature Metabolism reported a double-blind randomised trial of intermittent dasatinib plus quercetin in 31 people with fibrotic MASH. On paired liver biopsies, 47% on D+Q improved fibrosis by at least one stage without MASH getting worse, versus 7% on placebo. MASH resolution was also more common (53% vs 7%), and single-nucleus RNA sequencing showed lower senescence and fibrosis gene signatures.
Why it matters
This is a small proof-of-principle study with more self-limiting side effects on treatment, not a DIY longevity protocol. What interests me is the constructive signal: clearing senescent cells can move histology that usually resists easy change.
Evidence: Early · Phase-2 double-blind randomised trial; 31 people with fibrotic MASH, paired liver biopsies · 1 October 2026
Quick Signals
Signal 1
A mitochondrial membrane lipid steers how aging muscle adapts
What happened
As we age, muscle mitochondria lose cardiolipin, a specialised membrane lipid. A Nature Aging team showed that recreating that drop in young mice drives the familiar fast-to-slow fiber shift through an ERRγ mitochondria-to-nucleus signal, and the switch looks protective (more sugar routed into the cell's own antioxidant pathways). Partial restoration of cardiolipin synthesis started reversing muscle wasting and fully rescued premature mortality in the inducible model. Human muscle samples also show age-related cardiolipin decline.
Why it matters
This is preclinical work with human confirmation of the lipid drop, not a consumer antioxidant pitch. The hopeful part is a recovery lever on a membrane lipid most of us never think about.
Evidence: Early · Mouse experiments plus human muscle samples confirming the cardiolipin decline · 29 September 2026
Signal 2
Direct AMPK activation extends lifespan across three species
What happened
Most drug studies hit AMPK indirectly (think metformin), which muddies the longevity story. An Aging Cell paper used compound 991 to switch AMPK on directly. Lifespan rose in yeast, worms and flies. In mice, the same compound pushed proteomes toward a pro-longevity pattern.
Why it matters
Mouse healthspan and lifespan still need testing, and this is not a consumer longevity pill. What I like is the cleaner question it opens: if you can target the cell's energy-balance sensor directly, aging pharmacology gets a sharper tool.
Evidence: Early · Yeast, worm and fly lifespan studies plus mouse proteomics; mouse lifespan not yet tested · September 2026
What is one hopeful health story you saw this week that we should not miss? Hit reply. I read them.
Talk soon,LukasFounder of LongevityMate
Get the next Brief
Free health and longevity news, checked for evidence and sent every Tuesday.
Sign up for the free BriefBring the same evidence-first view to your own health data.
LongevityMate organises blood work, optional wearable context and goals to help you understand trends and prepare better questions. It does not diagnose, treat or replace a clinician.
See how LongevityMate worksLongevityMate Brief is educational information, not medical advice. Questions or feedback? Email hello@longevitymate.com.